Annovis Bio Inc (ANVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Annovis Bio Inc (ANVS) has a cash flow conversion efficiency ratio of -0.265x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.49 Million) by net assets ($13.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Annovis Bio Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Annovis Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ANVS current and long-term liabilities for a breakdown of total debt and financial obligations.
Annovis Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annovis Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KTIS Corporation
KO:058860
|
0.125x |
|
T Scientific Co.Ltd
KQ:057680
|
-0.008x |
|
Ekinops SA
PA:EKI
|
0.004x |
|
Sports Entertainment Group Ltd
AU:SEG
|
0.082x |
|
Country Group Holdings Public Company Limited
BK:CGH
|
-0.037x |
|
Ailleron S.A.
WAR:ALL
|
0.088x |
|
An-Shin Food Services Co Ltd
TWO:1259
|
0.060x |
|
Seowon
KO:021050
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Annovis Bio Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Annovis Bio Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Annovis Bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.31 Million | $-21.89 Billion | -2352.325x | -45718.55% |
| 2023-12-31 | $-7.75 Million | $-39.97 Million | 5.157x | +943.59% |
| 2022-12-31 | $28.32 Million | $-17.31 Million | -0.611x | -197.82% |
| 2021-12-31 | $44.49 Million | $-9.13 Million | -0.205x | +61.02% |
| 2020-12-31 | $7.54 Million | $-3.97 Million | -0.527x | -1047.67% |
| 2019-12-31 | $-8.58 Million | $-476.54K | 0.056x | -24.46% |
| 2018-12-31 | $-7.59 Million | $-558.61K | 0.074x | -4.67% |
| 2017-12-31 | $-6.97 Million | $-537.48K | 0.077x | +114.53% |
| 2012-12-31 | $2.66 Million | $-1.41 Million | -0.531x | -145.69% |
| 2011-12-31 | $13.93 Million | $-3.01 Million | -0.216x | -100.99% |
| 2010-12-31 | $16.49 Million | $-1.77 Million | -0.108x | +59.22% |
| 2009-12-31 | $1.48 Million | $-389.23K | -0.264x | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinic… Read more